INTRODUCTION: Chemokine receptors may regulate the progression and metastasis of invasive malignancies. There are little data, however, regarding their role in premalignant lesions. Our objective was to determine the role of CC chemokine receptor 9 (CCR9) in pancreatic intraepithelial neoplasia (PanIN). METHODS: Human and murine formalin-fixed paraffin-embedded (FFPE) PanIN specimens were assessed for CCR9 expression. The established murine PanIN, invasive pancreatic cancer (5143PDA) and liver metastasis (5143LM) cell lines, and human pancreatic cancer cell line (PANC-1) were obtained to verify CCR9 expression and function. RESULTS: Immunohistochemistry of FFPE specimens demonstrated CCR9 expression in both murine and human PanIN lesions. CCR9 expression in murine and human cell lines was verified by Western blot assay, immunofluorescence, and flow cytometry. CCR9 function was demonstrated by in vitro exposure to CCL25, the selective CCR9 ligand, which resulted in significantly increased cell proliferation in PanIN and pancreatic cancer cell lines. CONCLUSIONS: This is the first report of chemokine receptor CCR9 expression in murine and human PanIN tissues. Our results demonstrate enhanced PanIN and pancreatic cancer cell proliferation with activation of CCR9 by its selective ligand CCL25. CCR9 may prove to be a novel therapeutic target for PanIN and its progression to invasive cancer.
INTRODUCTION: Chemokine receptors may regulate the progression and metastasis of invasive malignancies. There are little data, however, regarding their role in premalignant lesions. Our objective was to determine the role of CC chemokine receptor 9 (CCR9) in pancreatic intraepithelial neoplasia (PanIN). METHODS:Human and murineformalin-fixed paraffin-embedded (FFPE) PanIN specimens were assessed for CCR9 expression. The established murine PanIN, invasive pancreatic cancer (5143PDA) and liver metastasis (5143LM) cell lines, and humanpancreatic cancer cell line (PANC-1) were obtained to verify CCR9 expression and function. RESULTS: Immunohistochemistry of FFPE specimens demonstrated CCR9 expression in both murine and humanPanIN lesions. CCR9 expression in murine and human cell lines was verified by Western blot assay, immunofluorescence, and flow cytometry. CCR9 function was demonstrated by in vitro exposure to CCL25, the selective CCR9 ligand, which resulted in significantly increased cell proliferation in PanIN and pancreatic cancer cell lines. CONCLUSIONS: This is the first report of chemokine receptor CCR9 expression in murine and human PanIN tissues. Our results demonstrate enhanced PanIN and pancreatic cancer cell proliferation with activation of CCR9 by its selective ligand CCL25. CCR9 may prove to be a novel therapeutic target for PanIN and its progression to invasive cancer.
Authors: A P Vicari; D J Figueroa; J A Hedrick; J S Foster; K P Singh; S Menon; N G Copeland; D J Gilbert; N A Jenkins; K B Bacon; A Zlotnik Journal: Immunity Date: 1997-08 Impact factor: 31.745
Authors: M A Wurbel; M Malissen; D Guy-Grand; E Meffre; M C Nussenzweig; M Richelme; A Carrier; B Malissen Journal: Blood Date: 2001-11-01 Impact factor: 22.113
Authors: R H Hruban; N V Adsay; J Albores-Saavedra; C Compton; E S Garrett; S N Goodman; S E Kern; D S Klimstra; G Klöppel; D S Longnecker; J Lüttges; G J Offerhaus Journal: Am J Surg Pathol Date: 2001-05 Impact factor: 6.394
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson Journal: Cancer Cell Date: 2003-12 Impact factor: 31.743
Authors: Sangjun Lee; Eileen L Heinrich; Lily Li; Jianming Lu; Audrey H Choi; Rachel A Levy; Jeffrey E Wagner; M L Richard Yip; Nagarajan Vaidehi; Joseph Kim Journal: Mol Oncol Date: 2015-05-12 Impact factor: 6.603
Authors: Eileen L Heinrich; Amanda K Arrington; Michelle E Ko; Carrie Luu; Wendy Lee; Jianming Lu; Joseph Kim Journal: Cancer Microenviron Date: 2013-02-01
Authors: Jiamin Zhou; Yi Xiang; Teizo Yoshimura; Keqiang Chen; Wanghua Gong; Jian Huang; Ye Zhou; Xiaohong Yao; Xiuwu Bian; Ji Ming Wang Journal: Biomed Res Int Date: 2014-07-10 Impact factor: 3.411
Authors: Sonia Chamorro; Maria Vela; Ana Franco-Villanueva; Laura Carramolino; Julio Gutiérrez; Lucio Gómez; María Lozano; Beatriz Salvador; Mónica García-Gallo; Carlos Martínez-A; Leonor Kremer Journal: MAbs Date: 2014-05-07 Impact factor: 5.857